



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



Tat-CIRP (trifluoroacetate salt)

Item No. 37446

Synonym: Tat-Cold-inducible RNA Binding Protein
Peptide Sequence: YGRKKRRQRRRGRGFSRGGGDRGYGG-OH
MF: C₁₂₃H₂₀₆N₅₆O₃₃ • XCF₃COOH
FW: 2,997.3
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years

H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Gly-Arg-Gly-Phe-Ser-Arg-Gly-Gly-Gly-Asp-Arg-Gly-Tyr-Gly-Gly-OH
• XCF₃COOH

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Tat-CIRP (trifluoroacetate salt) is supplied as a solid. A stock solution may be made by dissolving the Tat-CIRP (trifluoroacetate salt) in water. We do not recommend storing the aqueous solution for more than one day.

Description

Tat-CIRP is a peptide inhibitor of the protein-protein interaction between myeloid differentiation 2 (MD-2), also known as lymphocyte antigen 96 (LY96), and cold-inducible RNA binding protein (CIRP).¹ It binds to MD-2 and disrupts the interaction between MD-2 and CIRP in co-immunoprecipitation assays. *In vivo*, Tat-CIRP (10 and 20 mg/kg) reduces infarct volume in a mouse model of stroke induced by middle cerebral artery occlusion (MCAO). It also reduces infarct volume and decreases the time to pick up and withdraw food with the stroke-affected arm in a rhesus monkey model of thrombosis-induced stroke.

Reference

1. Fang, Z., Wu, D., Deng, J., et al. An MD2-perturbing peptide has therapeutic effects in rodent and rhesus monkey models of stroke. *Sci. Transl Med.* **13**(597), eabb6716 (2021).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/09/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM